Dendreon Corp fka DNDNQ

[tourburn]

<Cross-over is less of any issue, because it only causesd provenge to appear less effective than it would have been without the crossover. Bulls, bears and shorts seem to agree on this one.>

That's my point. We end up questioning the support that 9902A gives the 9901 results. But the results deal more with whether early Provenge is better than later Provenge (as a result of the crossovers). Meanwhile the FDA decision is to determine if Provenge should be provided at all.